Avoiding CMC pitfalls

The completion of the Chemistry, Manufacturing, and Controls (CMC) section of a cell therapy Investigational New Drug (IND) application is crucial in demonstrating to FDA and other regulatory bodies that an investigational product can be consistently manufactured while meeting safety, identity, quality, purity and potency standards. There are often, however, many hidden yet avoidable CMC pitfalls and issues.

A clear CMC roadmap is critical as global regulators expect to see not only a snapshot of current controls but a clear path showing how a process will mature and scale throughout development and commercialization. Beginning intentional CMC planning and execution in early development phases allows anticipation of potential regulatory snags, manufacturing scalability issues, and costly rework before these risks become existential threats.

A living CMC roadmap can, in fact, successfully guide a cell therapy program throughout the development life cycle, including identifying critical quality attributes (CQAs) early, designing scalable processes, and implementing rigorous, phase-appropriate analytical methods. Access to such a roadmap helps cell therapy developers stay ahead of risk and accelerate development.

What does a dynamic CMC roadmap entail?

A living CMC roadmap provides a structured framework for managing the program throughout the development life cycle, including early identification of critical quality attributes, scalable process design, and implementation of rigorous, phase-appropriate analytical methods. As programs advance, the roadmap evolves to ensure all regulatory expectations are met and/or exceeded and a path is mapped out not just to IND filing, but through the biological license application (BLA) submission.

The phase 1 CMC roadmap for cell therapies includes establishing target product profiles, defining CQAs such as phenotype, identity, purity and viability, and linking them to clinical relevance using robust, fit-for-purpose methods. A well-defined development roadmap is also established that minimizes identified risks and addresses IND submission milestones and timeline and cost considerations.

As a program moves into clinical development, the strategy focuses on addressing clinical trial needs with respect to the target population, dosing and desired outcomes. Late-stage and commercial success is then enabled by defining the path to BLA submission leveraging expertise in process scaling, GMP manufacturing capabilities, and regulatory compliance.

Throughout all phases, expertise in analytics and quality control is essential for ensuring effective design, qualification, and phase-appropriate validation of potency, safety, identity, purity and other critical assays. Building these tools with sufficient flexibility to provide early-phase insights yet allow for necessary refinements as the program matures requires the right balance of scientific rigor and practical adaptability. When done correctly, it is possible to avoid overengineering early on but still efficiently add robustness as the program advances.

Partnering with a cell therapy CDMO that collaborates on development of a dynamic CMC roadmap and works closely with clients to craft proactive process and analytical optimization strategies can also help ensure a holistic framework for future-proofing regulatory submissions, minimizing costly surprises and facilitating both speed and quality.

Anticipate potential regulatory snags

Meeting CMC regulatory requirements is essential to achieving successful IND and BLA filings. That can be challenging for cell therapy developers given that cell therapy approaches and technologies are evolving quickly, and consequently, regulatory guidance is also changing rapidly. Indeed, over the last two years, a significant percentage of FDA complete response letters (CRLs) have been attributed to insufficient CMC packages rather than issues related to therapeutic product safety or efficacy.^1,2 In addition, incomplete or fragmented CMC narratives, missing risk assessments, and weak justification of specifications and/or acceptance criteria slow reviews.

Early, phase-appropriate alignment with guidance is key, and pre-IND and pre-BLA meetings with the FDA are ideal opportunities to ensure alignment with regulatory expectations and secure FDA buy-in on a phase-appropriate CMC strategy. Pre-IND dialogue is the first — and sometimes the only — opportunity to secure FDA buy-in, which can help avoid development delays. FDA’s Office of Therapeutic Products (OTP) expressly invites CMC questions during Type B Pre-IND meetings for complex products and processes, including cell therapies.

Key topics related to preclinical through phase 2 development that are important to address in pre-IND CMC discussions include assay qualification, raw material sourcing, comparability protocols, pilot-run and preliminary stability data, draft specifications, process optimization strategies and potential bridging studies. It is also beneficial to confirm phase-appropriate expectations and reach agreement on when full validation will be required. This approach supports the establishment of tangible milestones, reducing uncertainty and avoiding regulatory delays.

Ensure manufacturing scalability

Successful translation of new cell therapies from concept to the clinic and commercialization requires development of manufacturable products that can be produced efficiently using robust, scalable processes. Once the CQAs are defined, an effective CMC roadmap addresses both process and analytical development aspects, including comprehensive process definition, identification, validation of analytical methods, and establishment of a suitable process control strategy.

Initial processes should enable cost-effective production of non-GMP material for preclinical studies and generate data to support the IND. Subsequent process and analytical optimization should deliver GMP-compliant clinical trial material and validated/qualified methods for GMP release. The CMC roadmap should also include fit-for-purpose stability studies (e.g., freeze-thaw effects, in-process holds, and shelf life) and raw-material risk management (vendor oversight, GMP qualification of critical materials, and chain-of-identity/chain-of-custody controls for patient-derived inputs).

Finally, because cell therapies must be produced using aseptic processes, sterility assurance and contamination control represent major aspects of cell therapy manufacturing that must be addressed as programs advance and processes scale. Regulators scrutinize aseptic processing, environmental monitoring data, sterility strategies, mycoplasma testing, the control of adventitious agents, and particulates. The CMC roadmap takes into account these considerations for all operations, especially those that employ open systems and involve manual interventions.

Avoid costly rework

By anticipating regulatory snags and ensuring manufacturing scalability, cell therapy producers position themselves for efficient advancement of clinical programs. Potential opportunities remain, however, for complications that lead to the need for costly rework of production batches. These issues can be avoided if the CMC roadmap includes thoughtful strategies for process and method optimization, characterization and validation; comparability study design and execution; and specification assessment and refinement.

Autologous, patient-derived cell therapies can be influenced by patient health, variability in prior lines of therapy and apheresis collection — all of which contribute to greater lot-to-lot variability. For allogeneic, off-the-shelf treatments, the greatest challenges are scale-related. For both, an effective CMC roadmap prevents manufacturing variability by establishing a clear control strategy with in-process controls, defined acceptance criteria and a robust validation approach.

As cell therapy programs advance toward commercialization, changes are inevitable. Robust comparability data must show that changes in materials, process, scale, or site do not compromise safety, quality or potency. A strong CMC roadmap therefore should include risk-based, data-rich retain and comparability plans.

Building a solid plan early in the development cycle helps reduce risk and keep approvals on track by expediting the submission process. At Kincell Bio, key components of our approach to development for clinical success include:

• using a design-of-experiment (DoE) approach to increase the efficiency of process and analytical development;
• employing a mix of platform and product-specific manufacturing unit operations for improved COGs;
• leveraging collaborative decision-making to balance process performance with time to the clinic;
• conducting thorough assessments to minimize variability impacts; and
• applying phase-appropriate analytical control strategies.

Reaching commercial readiness and approval without the need for rework also requires consideration of other challenging aspects specifically related to cell therapy development and manufacturing. Facilities and operations must align with the needs of the cell therapy produced with respect to the quality system maturity, data integrity, deviation/corrective and preventive action (CAPA) management, training, computer systems, quality risk management, and pre-approval inspection readiness. Alignment on donor screening, testing, traceability and transport conditions must be assured. For gene-modified cells, vector and/or editing reagent quality, residuals, replication-competent virus testing, insertional mutagenesis risks, vector copy number, on- and off-target editing and transgene expression kinetics must all be considered. An effective CMC roadmap addresses all these issues.

References

1. Foster, B. (2025, Aug. 3). Why gene and cell therapies are stalling at the FDA. Drug Discovery News.
2. Armstrong, A. (2025, Sept. 4). FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access. BioSpace.